ArticleScientific reports2026
Glutamine promotes acute wound healing by mediating glutamine metabolism and M2 macrophage polarization via the MEK/ERK/SLC1A5 signaling pathway.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed, 1 synthesis or guideline pooled it.
- SIRT3 in post-myocardial infarction macrophage reprogramming: linking mitochondrial fitness to inflammation resolution and repair.Frontiers in immunology · 2026Pooled it
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
To demonstrate glutamine (Gln) promotes acute wound healing by mediating Gln metabolism and macrophage M2 polarization through the Mitogen-Activated Protein Kinase Kinase (MEK)/Extracellular Regulated Protein Kinases (ERK)/Solute Carrier Family 1 Member 5 (SLC1A5) signaling axis.Thirty C57BL/6J mice were used to establish a full-thickness skin defect model and randomly divided into six groups (n = 5 per group): Control group, Model group, Gln treatment group (Gln), Gln combined with MEK inhibitor U0126 group (Gln + MEK inhibitor), Gln combined with GLS1 inhibitor group (Gln+GLS1 inhibitor), and Gln combined with SLC1A5 inhibitor group (Gln+SLC1A5 inhibitor). Immunofluorescence (IF) was used to detect the angiogenesis marker CD31, the fibroblast activation marker α-smooth muscle actin (α-SMA), and macrophage polarization markers (CD86 for M1, CD206 for M2). Gln upregulates the expression of SLC1A5 by activating MEK/ERK pathway, thus promoting Gln metabolic reprogramming and accelerating acute wound healing. This subsequently drives M2 macrophage polarization, angiogenesis, and tissue remodeling. Our findings elucidate the critical role of the Gln metabolism-immune regulation axis in wound repair and provide a novel therapeutic target for metabolically targeted wound interventions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.